Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Treatment
  4. /
  5. Interferon alfa-2a (recombinant)

Interferon alfa-2a (recombinant)

April 12, 2017
Interferon alfa-2a (recombinant)
Trade Name Roferon-A
Orphan Indication Metastatic Melanoma
USA Market Approval USA
USA Designation Date 1990-05-11 00:00:00
Sponsor Hoffmann-La Roche, Inc.;340 Kingsland Street;Nutley, New Jersey, 07119
Related Access Program
Merck Sharp & Dohme Corp. – Metastatic Melanoma Eli Lilly and Company – Metastatic Melanoma Bristol-Myers Squibb – Metastatic Melanoma Bristol-Myers Squibb – Metastatic Melanoma

Related Treatment

  • Indoximod
  • Fully human monoclonal antibody specific for lymphocyte activation gen
  • Thymalfasin
  • Talimogene laherparepvec
  • Sorafenib
More Treatment
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2024 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo